Hcw Biologics Stock Current Valuation
| HCWB Stock | USD 0.37 0.05 11.90% |
Valuation analysis of HCW Biologics helps investors to measure HCW Biologics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 62.7 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (2.01). Fundamental drivers impacting HCW Biologics' valuation include:
Price Book 2.7998 | Enterprise Value 22.9 M | Enterprise Value Ebitda (3.63) | Price Sales 3.5686 | Enterprise Value Revenue 5.8281 |
Undervalued
Today
Please note that HCW Biologics' price fluctuation is extremely dangerous at this time. Calculation of the real value of HCW Biologics is based on 3 months time horizon. Increasing HCW Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since HCW Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HCW Stock. However, HCW Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.37 | Real 1.77 | Target 6.0 | Hype 0.36 | Naive 0.29 |
The real value of HCW Stock, also known as its intrinsic value, is the underlying worth of HCW Biologics Company, which is reflected in its stock price. It is based on HCW Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of HCW Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of HCW Biologics helps investors to forecast how HCW stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HCW Biologics more accurately as focusing exclusively on HCW Biologics' fundamentals will not take into account other important factors: HCW Biologics Company Current Valuation Analysis
HCW Biologics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current HCW Biologics Current Valuation | 22.86 M |
Most of HCW Biologics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HCW Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
HCW Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for HCW Biologics is extremely important. It helps to project a fair market value of HCW Stock properly, considering its historical fundamentals such as Current Valuation. Since HCW Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of HCW Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of HCW Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
HCW Current Valuation Historical Pattern
Today, most investors in HCW Biologics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various HCW Biologics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of HCW Biologics current valuation as a starting point in their analysis.
HCW Biologics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, HCW Biologics has a Current Valuation of 22.86 M. This is 99.84% lower than that of the Biotechnology sector and 99.51% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.86% higher than that of the company.
HCW Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HCW Biologics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HCW Biologics could also be used in its relative valuation, which is a method of valuing HCW Biologics by comparing valuation metrics of similar companies.HCW Biologics is currently under evaluation in current valuation category among its peers.
HCW Fundamentals
| Return On Equity | -3.44 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (22.36) % | ||||
| Current Valuation | 22.86 M | ||||
| Shares Outstanding | 37.82 M | ||||
| Shares Owned By Insiders | 52.30 % | ||||
| Shares Owned By Institutions | 3.10 % | ||||
| Number Of Shares Shorted | 24.89 K | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 3.57 X | ||||
| Revenue | 2.84 M | ||||
| Gross Profit | 4.1 M | ||||
| EBITDA | (24.58 M) | ||||
| Net Income | (24.99 M) | ||||
| Cash And Equivalents | 32.41 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 6.45 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 30.25 X | ||||
| Book Value Per Share | (0.17) X | ||||
| Cash Flow From Operations | (22.51 M) | ||||
| Short Ratio | 1.06 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 45 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 14 M | ||||
| Total Asset | 28.51 M | ||||
| Retained Earnings | (70.53 M) | ||||
| Working Capital | (2.34 M) | ||||
| Net Asset | 28.51 M |
About HCW Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HCW Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HCW Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HCW Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out HCW Biologics Piotroski F Score and HCW Biologics Altman Z Score analysis. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.